DA-8159, a Potent cGMP Phosphodiesterase Inhibitor, Attenuates Monocrotaline-Induced Pulmonary Hypertension in Rats |
Kang, Kyung-Koo
(Research Laboratories, Dong-A Pharm. Co. Ltd.)
Ahn, Gook-Jun (Research Laboratories, Dong-A Pharm. Co. Ltd.) Sohn, Yong-Sung (Research Laboratories, Dong-A Pharm. Co. Ltd.) Ahn, Byoung-Ok (Research Laboratories, Dong-A Pharm. Co. Ltd.) Kim, Won-Bae (Research Laboratories, Dong-A Pharm. Co. Ltd.) |
1 | McMahon, T. J., Ignarro, L. J., and Kadowitz, P. J., Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J. Appl. Physiol., 74, 1704-1711 (1993) DOI PUBMED |
2 | Pepke-Zaba, J., Higenbottam, T. W., Dinh-Xuan, A. T., Stone, D., and Wallwork, J., Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet, 338, 1173-1174 (1991) DOI ScienceOn |
3 | Polson, J. B. and Strada, S. J., Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol., 36, 403-427 (1996) DOI ScienceOn |
4 | Prasad, S., Wilkinson, J., and Gatzoulis, M. A., Sildenafil in primary pulmonary hypertension. N. Engl. J. Med., 343, 1342 (2000) DOI PUBMED ScienceOn |
5 | Rich, S., Dantzker, D. R., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., and Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med., 107, 216-223 (1987) DOI PUBMED ScienceOn |
6 | Schermuly, R. T., Roehl, A., Weissmann, N., Ghofrani, H. A., Leuchte, H., Grimminger, F., Seeger, W., and Walmrath, D., Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol., 281, L1361-L1368 (2001b) DOI PUBMED |
7 | Troncy, E., Francoeur, M., and Blaise, G., Inhaled nitric oxide: clinical applications, indications, and toxicology. Can. J. Anaesth., 44, 973-988 (1997) DOI ScienceOn |
8 | Kodama, K. and Adachi, H., Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J. Pharmacol. Exp. Ther., 290, 748-752 (1999) PUBMED |
9 | Frostell, C., Fratacci, M. D., Wain, J. C., Jones, R., and Zapol, W. M., Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation, 83, 2038-2047 (1991) DOI PUBMED ScienceOn |
10 | Braner, D. A., Fineman, J. R., Chang, R., and Soifer, S. J., M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol., 264, H252-H258 (1993) PUBMED |
11 | Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., and Wilkins, M. R., Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104, 424-428 (2001) DOI ScienceOn |
12 | Shim, H. J., Lee, E. J., Kim, S. H., Yoo, M., Kim, W. B., Lee, H. S., and Lee, M. G., Pharmacokinetics and metabolism of DA-8159, A new PDE5 inhibitor. 8th Asia-Pacific Society for Impotence Research & Exhibition. Thailand, OR5-5 (2001) |
13 | Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., Koerner, S. K., Langleben, D., Keller, C. A., Murali, S., Uretsky, B. F., Clayton, L. M., Jobsis, M. M., Blackburn, S. D., Shortino, D., and Crow, J. W., A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med., 334, 296-302 (1996)⨀ ₙ얖⨀ ⨀ ȄĀ ᣦ⨀ ゴ얖⨀ 裺⨀ ĄȀ ?⨀ 낰얖⨀ 裺⨀ ĄȀ ᣩ⨀ 얖⨀ 裺⨀ ĄȀ 㣩⨀ ®얖⨀ 裺⨀ ĄȀ 䣩⨀ ?얖⨀ 裺⨀ ĄȀ 飨⨀ ₭얖⨀ 裺⨀ ĄȀ 壩⨀ 䂬얖⨀ 裺⨀ ĄȀ 棩⨀ 傳얖⨀ 裺⨀ ĄȀ ⨀ 悫얖⨀ 裺⨀ ĄȀ 磩⨀ 肪얖⨀ 裺⨀ ĄȀ 裩⨀ 炲얖⨀ 裺⨀ ĄȀ ⨀ 邱얖⨀ 裺⨀ ĄȀ ࣩ⨀ ꂩ얖⨀ 裺⨀ ĄȀ 飩⨀ 삨얖⨀ 裺⨀ ĄȀ ꣩⨀ 얖⨀ 裺⨀ ĄȀ 룩⨀ §얖⨀ 裺⨀ ĄȀ 죩⨀ ₦얖⨀ 裺⨀ ĄȀ ?⨀ 䂥얖⨀ 裺⨀ ĄȀ ⨀ ?얖⨀ 裺⨀ ĄȀ ⨀ 얖⨀ 裺⨀ ĄȀ ࣪⨀ ᣃ얖⨀ 裺⨀ ĄȀ DOI ScienceOn |
14 | Weimann, J., Ullrich, R., Hromi, J., Fujino, Y., Clark, M. W., Bloch, K. D., and Zapol, W. M., Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology, 92, 1702-1712 (2000) DOI ScienceOn |
15 | Pichardo, J., Palace, V., Farahmand, F., and Singal, P. K., Myocardial oxidative stress changes during compensated right heart failure in rats. Mol. Cell Biochem., 196, 51-57 (1999) DOI PUBMED ScienceOn |
16 | Rosenkrantz, J. G., Lynch, F. P., and Vogel, J. H., Hypoxic pulmonary hypertension: its modification by dipyridamole. J. Surg. Res., 12, 330-333 (1972) DOI ScienceOn |
17 | Schermuly, R. T., Krupnik, E., Tenor, H., Schudt, C., Weissmann, N., Rose, F., Grimminger, F., Seeger, W., Walmrath, D., and Ghofrani, H. A., Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am. J. Respir. Crit. Care. Med., 164, 1694-1700 (2001a) DOI PUBMED ScienceOn |
18 | Thomas, M. K., Francis, S. H., and Corbin, J. D., Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem., 265, 14964-14970 (1990) PUBMED |
19 | Abrams, D., Schulze-Neick, I., and Magee, A. G., Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart, 84, E4 (2000) DOI PUBMED |
20 | Cohen, A. H., Hanson, K., Morris, K., Fouty, B., McMurty, I. F., Clarke, W., and Rodman, D. M. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest., 97, 172-179 (1996) DOI PUBMED |
21 | Wilkens, H., Guth, A., Konig, J., Forestier, N., Cremers, B., Hennen, B., Bohm, M., and Sybrecht, G. W., Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation, 104, 1218-1222 (2001) DOI ScienceOn |
22 | Ziegler, J. W., Ivy, D. D., Wiggins, J. W., Kinsella, J. P., Clarke, W. R., and Abman, S. H., Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med., 158, 1388-1395 (1998) DOI PUBMED ScienceOn |
23 | Yamaguchi, K., Oka, M., Nishino, M., Hanasato, N., Kira, S., and Fukuchi, Y., E4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats. Nihon Kokyuki Gakkai Zasshi, 36, 23-28 (1998) PUBMED |
24 | Dukarm, R. C., Russell, J. A., Morin, F. C ., Perry, B. J., and Steinhorn, R. H., The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation. Am. J. Respir. Crit. Care. Med., 160, 858-865 (1999) DOI PUBMED ScienceOn |
25 | Nakazawa, H., Hori, M., Ozaki, H., and Karaki, H., Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br. J. Pharmacol., 128, 1098-1104 (1999) DOI ScienceOn |
26 | Dinerman, J. L., Lowenstein, C. J., and Snyder, S. H., Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ. Res., 73, 217-222 (1993) DOI PUBMED ScienceOn |
27 | Takahashi, T., Kanda, T., Inoue, M., Suzuki, T., Kobayashi, I., Kodama, K., and Nagai, R., A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci., 59, PL371-PL377 (1996) DOI ScienceOn |
28 | Rosenberg, H. C. and Rabinovitch, M., Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am. J. Physiol., 255, H1484-H1491 (1998) |
29 | Schultze, A. E. and Roth, R. A., Chronic pulmonary hypertension- the monocrotaline model and involvement of the hemostatic system. J. Toxicol. Environ. Health B Crit. Rev., 1, 271-346 (1998) DOI PUBMED ScienceOn |
30 | Chen, L., Gan, X. T., Haist, J. V., Feng, Q., Lu, X., Chakrabarti, S., and Karmazyn, M., Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the exchange inhibitor cariporide. J. Pharmacol. Exp. Ther., 298, 469-476 (2001) PUBMED |
31 | Dundore, R. L., Clas, D. M., Wheeler, L. T., Habeeb, P. G., Bode, D. C., Buchholz, R. A., Silver, P. J., and Pagani, E. D., Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. Eur. J. Pharmacol., 249, 293-297 (1993) DOI ScienceOn |
32 | Hanasato, N., Oka, M., Muramatsu, M., Nishino, M., Adachi, H., and Fukuchi, Y., E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am. J. Physiol., 277, L225-L232 (1999) DOI PUBMED |
33 | Cassis, L. A., Rippetoe, P. E., Soltis, E. E., Painter, D. J., Fitz, R., and Gillespie, M. N., Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. J. Pharmacol. Exp. Ther., 262, 1168-1172 (1992) PUBMED |